Archive explorer

Browse & search snapshots

Important note

Browse and search historical snapshots. This is an archive — not current guidance or medical advice. Archived content may be incomplete, outdated, or superseded. For up-to-date recommendations, always consult the official source website.

For background on coverage and capture methods, see Methods & coverage.

Browse archived sites

Browse all sources →

Dear health care professional letter: Albrioza (PDF Version - 124 K) Health Canada posts safety alerts, public health advisories, press releases and other notices from industry as a service to health professionals, consumers, and other interested parties. Although Health Canada…

Canadian Generic Pharmaceutical Association (CGPA): Final record of decisions June 3, 2021 Health Canada, Health Products and Food Branch (HPFB) Bilateral Meeting Program Virtual June 3, 2021 1:00 p.m. to 3:50 p.m. On this page Participants and observers Meeting minutes Next…

Consultation: Notice of intent to amend the regulations to address health product shortages in Canada Current status: Closed Opened from June 25 to July 25, 2024. Health Canada is proposing to amend the Food and Drug Regulations and the Medical Devices Regulations to: help…

Draft guidance on expanded access clinical trials: Closed consultation From: Health Canada Current status: Closed This consultation ran from August 2 to October 31, 2024. Health Canada has published a draft guidance document on expanded access clinical trials. This document…

Groupement provincial de l’industrie du médicament (GPIM): Final record of decisions April 21, 2022 Health Canada, Health Products and Food Branch (HPFB) Bilateral Meeting Program Virtual April 21, 2022 1:00 p.m. to 2:45 p.m. On this page Participants and observers Meeting…

Notice: Multiple additions to the Prescription Drug List (PDL) [2024-08-13] August 13, 2024 Our file number: 24-107297-36 The purpose of this Notice of Amendment is to notify about the addition of capromorelin (veterinary), eplontersen, lebrikizumab, talquetamab, and zilucoplan…

Notice - Release of the final guidance document: “Switching from prescription to non-prescription status” August 14, 2024 Our file number: 24-106412-576 Health Canada is pleased to announce the release of the final version of the guidance document: “Switching from prescription to…

Notice: Publication of the Guidance Document: Certificates of Supplementary Protection August 19, 2024 Our reference number: 24-107332 - 41 Health Canada is pleased to announce an update to the Guidance Document: Certificates of Supplementary Protection . The Office of Patented…

Qualifying notice for Imdelltra - Canada.ca

Health CanadaCaptures 12Latest capture Apr 11, 2026en

Qualifying notice for Imdelltra (281963) Biologic and Radiopharmaceutical Drugs Directorate 100 Eglantine Driveway LCDC Building Tunney's Pasture, A.L. 0601C Ottawa ON K1A 0K9 Dossier ID: E271976 Control Number: 281963 [name of employee removed] [employee title removed] Amgen…

Innovative Medicines Canada (IMC): Final record of decisions May 17, 2022 Health Canada, Health Products and Food Branch (HPFB) Bilateral Meeting Program Virtual May 17, 2022 1:00 p.m. to 3:10 p.m. On this page Participants Meeting minutes Next meeting Participants IMC…

Page 4287 of 6399Showing 42861-42870 of 63986

Early release: coverage and features are still expanding.